On 11 August 2026, Brazil’s INPI announced the launch of a collaborative patent examination project with Peru’s INDECOPI, beginning with nine applications. The first batch targets pharmaceuticals, including medicinal chemistry and biopharmaceuticals, biotechnology and natural products. Eligible cases were filed through the PCT route, have corresponding family applications in both Brazil and Peru, and entered the national phase within the project’s specified window. Selected applications move ahead of the ordinary examination queue, and the project does not use a preliminary technical office action before the normal substantive examination process continues at each office.
The practical attraction is not speed alone. Life-sciences and natural-product patents can raise overlapping questions about claim scope, disclosure, prior art and, in some cases, biodiversity-related compliance. Applicants with parallel Brazilian and Peruvian filings may gain from less duplicated search work and earlier examination, but coordinated review should not be read as a promise of identical outcomes. A sensible response is to align claim strategy, specification support and national-phase records before accelerated examination exposes inconsistencies between the two files.
